Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27297
Title: Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial.
Austin Authors: Scheffer, Ingrid E ;Halford, Jonathan J;Miller, Ian;Nabbout, Rima;Sanchez-Carpintero, Rocio;Shiloh-Malawsky, Yael;Wong, Matthew;Zolnowska, Marta;Checketts, Daniel;Dunayevich, Eduardo;Devinsky, Orrin
Affiliation: Medicine (University of Melbourne)
Medical University of South Carolina, Charleston, South Carolina, USA..
Nicklaus Children's Hospital, Miami, Florida, USA..
Necker Enfants Malades Hospital, Imagine Institute, University of Paris, Paris, France..
Pediatric Neurology Unit, Pamplona, Spain..
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA..
Wake Forest School of Medicine, Winston-Salem, North Carolina, USA..
Medical Center Pleiades, Krakow, Poland..
GW Research, Cambridge, United Kingdom..
Greenwich Biosciences, Carlsbad, California, USA..
NYU Langone Comprehensive Epilepsy Center, New York, New York, USA..
Issue Date: 18-Aug-2021
Date: 2021
Publication information: Epilepsia 2021; 62(10): 2505-2517
Abstract: Add-on cannabidiol (CBD) reduced seizures associated with Dravet syndrome (DS) in two randomized, double-blind, placebo-controlled trials: GWPCARE1 Part B (NCT02091375) and GWPCARE2 (NCT02224703). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or GWPCARE2, were enrolled in a long-term open-label extension trial, GWPCARE5 (NCT02224573). We present an interim analysis of the safety, efficacy, and patient-reported outcomes from GWPCARE5. Patients received a pharmaceutical formulation of highly purified CBD in oral solution (100 mg/ml), titrated from 2.5 to 20 mg/kg/day over a 2-week period, added to their existing medications. Based on response and tolerance, CBD could be reduced or increased to 30 mg/kg/day. Of the 330 patients who completed the original randomized trials, 315 (95%) enrolled in this open-label extension. Median treatment duration was 444 days (range = 18-1535), with a mean modal dose of 22 mg/kg/day; patients received a median of three concomitant antiseizure medications. Adverse events (AEs) occurred in 97% patients (mild, 23%; moderate, 50%; severe, 25%). Commonly reported AEs were diarrhea (43%), pyrexia (39%), decreased appetite (31%), and somnolence (28%). Twenty-eight (9%) patients discontinued due to AEs. Sixty-nine (22%) patients had liver transaminase elevations >3 × upper limit of normal; 84% were on concomitant valproic acid. In patients from GWPCARE1 Part B and GWPCARE2, the median reduction from baseline in monthly seizure frequency assessed in 12-week periods up to Week 156 was 45%-74% for convulsive seizures and 49%-84% for total seizures. Across all visit windows, ≥83% patients/caregivers completing a Subject/Caregiver Global Impression of Change scale reported improvement in overall condition. We show that long-term CBD treatment had an acceptable safety profile and led to sustained, clinically meaningful reductions in seizure frequency in patients with treatment-resistant DS.
URI: https://ahro.austin.org.au/austinjspui/handle/1/27297
DOI: 10.1111/epi.17036
ORCID: 0000-0002-2311-2174
0000-0003-1681-6744
0000-0003-0416-1015
0000-0002-5058-0686
0000-0003-0044-4632
Journal: Epilepsia
PubMed URL: 34406656
Type: Journal Article
Subjects: Dravet syndrome
antiseizure medication
cannabinoid
childhood onset epilepsy
convulsive seizures
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on May 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.